Method for increasing body height comprising systemic administration of CNP-53
This invention provides a composition for increasing a body height of a patient with short stature or an individual other than patients with short stature. More specifically, the invention provides: a composition for increasing the body height of an individual comprising a guanyl cyclase B (GC-B) activator as an active ingredient, the composition being to be administered to an individual free from FGFR3 abnormality; a method for increasing the body height of an individual free from FGFR3 abnormality which comprises activating GC-B; a method for screening an agent for increasing the body height of an individual which comprises selecting an agent for increasing the body height using GC-B activity as an indication; and a method for extending a cartilage bone free from FGFR3 abnormality which comprises activating GC-B in an individual.
1. A method for increasing the body height of an individual free from fibroblast growth factor receptor 3 (FGFR3) abnormality, comprising administering systemically C-type natriuretic peptide (CNP) or a derivative thereof to increase the body height in the individual,
wherein the individual has growth cartilage layers,
wherein the CNP is CNP-53 of SEQ ID NO: 2,
wherein the derivative is selected from the group consisting of: CNP derivatives which are obtained from the amino acid sequence of SEQ ID NO: 2 by replacing all of residues 32-53 of SEQ ID NO:2 with a sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 3 to 10, wherein the CNP derivatives possess a CNP activity.
2. The method of claim 1 , wherein the increase in body height is extension of cartilage bones.
3. The method of claim 1 , wherein the increase in body height is extension of femora, tibiae, radiuses, or ulnae.
4. The method of claim 1 , wherein the CNP or the derivative thereof is CNP-53 of SEQ ID NO:2.
5. A method for extending a cartilage bone free from FGFR3 abnormality in an individual, comprising administering systemically C-type natriuretic peptide (CNP) or a derivative thereof to activate guanyl cyclase B (GC-B) in the individual,
wherein the individual has growth cartilage layers,
wherein the CNP is CNP-53 of SEQ ID NO: 2,
wherein the derivative is selected from the group consisting of: CNP derivatives which are obtained from the amino acid sequence of SEQ ID NO: 2 by replacing all of residues 32-53 of SEQ ID NO:2 with a sequence selected from the group consisting of the amino acid sequences of SEQ ID NOs: 3 to 10, wherein the CNP derivatives possess a CNP activity.